Indian Immunologicals Limited

IIL announced MoU signing and partnership with Central Institute of Brackishwater Aquaculture (CIBA), an Indian Council of Agricultural Research Institute for the commercial development of a recombinant monovalent viral nervous necrosis vaccine for finfish. Click on the below links to read the full news articles: APN: https://lnkd.in/dx_NJZDb Press Information Bureau Government of India: https://lnkd.in/d7277GWA Telangana Today: https://lnkd.in/djuU7ZeH Express Pharma: https://lnkd.in/dCYvQqZr

Today Indian Immunologicals Ltd. announced MoU signing and partnership with Central Institute of Brackishwater Aquaculture (CIBA), an Indian Council of Agricultural Research Institute for the commercial development of a recombinant monovalent viral nervous necrosis vaccine for finfish. Speaking on the occasion, Dr K Anand Kumar, Managing Director, Indian Immunologicals Limited said, “IIL is the first in India to get to fish vaccines. We are covering different kind of fishes (fresh water, brackish water, etc.) and culture conditions (pond, cage culture, etc.) and are aware of the challenges associated with being the first, having been in similar situations for many other livestock vaccines. We are working at multiple fronts in defining pathways for commercial development of fish vaccines in India".    IIL ventured into aqua business in October 2022 by launching products for aquaculture health market dealing with pond management and fish or shrimp gut management and subsequently announced commercial development of fish vaccines with ICAR’s CIFE, Mumbai and CIFA, Bhubaneswar. India is the 3rd largest fish producer in the global sphere and more than 65% of India’s fish is through Inland Fisheries and Aquaculture. The main constraint to aquaculture globally, however, is disease with an estimate that 20% of all cultured aquatic animals are lost because of infectious diseases, amounting to >10 billion USD in losses annually on a global scale. Aquaculture in India suffers economic losses due to infections caused by several bacterial, viral, fungal, and other aetiological agents. Currently these infections are being managed by anti-infectives and other conventional measures with varying degree of success. With the rising concern pertaining on anti-microbial resistance (AMR) and chemical free food products both at global and domestic platforms, there is a growing need for better control measures against these infections. Viral nervous necrosis (VNN) or viral encephalopathy and retinopathy (VER) is an acute viral disease affecting several species of marine, brackishwater and freshwater fishes. The disease causes up to 100% mortality in larval and early juvenile stages. Adult fish when infected, is asymptomatic, but can transmit the virus to the offspring through eggs and gonadal fluids. Currently there is no fish vaccines available in India on a commercial scale to prevent aquaculture infections. Dr. Priyabrata Pattnaik, Deputy Managing Director, Indian Immunologicals Limited added “IIL as a leading “One Health” organization is committed to developing vaccines for different fish pathogens with a long-term strategic objective of reducing use of antibiotics in aquaculture there by antimicrobial resistance in environment”. National Dairy Development Board

Our groundbreaking work Covid-19 vaccine, a live-attenuated needle free intra-nasal booster vaccine developed against SARS-CoV-2 using codon deoptimization technology, has been published in the world’s leading science Journal ‘Nature Communications’ on 26th August 2024. Dr K Anand Kumar, Managing Director, Indian Immunologicals Limited said, “This accomplishment signifies a major step forward in our battle against COVID-19. The development of this vaccine not only highlights our dedication to innovation in public health but also demonstrates IIL’s capability in adopting novel technology. We are enthusiastic about the codon de-optimization technology, and it’s use in targeted attenuation of microorganisms to be used as vaccine candidate”. Among different formats of vaccines available, it is well known that live attenuated vaccine generates a robust and broad-spectrum neutralizing antibody response. IIL’s needle free intra-nasal booster vaccine against SARS-CoV-2 developed using codon deoptimization technology demonstrated remarkable stability and maintained safety in extensive animal studies. Codon deoptimization involves decreasing the frequency of underrepresented codon pairs (genetic determinant for amino acids) without changing amino acid sequences. It is a highly efficient virus attenuation strategy that utilizes suboptimal codon pairs to achieve attenuation of recoded viruses. Virtually all the viruses can be attenuated by this method. Degree of attenuation can be regulated from 1-100% as required. It is extremely safe and less time-consuming than the conventional way of attenuating viruses, which usually takes several years. Completely guided attenuation and the means are well known, and attenuated virus is expected to present all the antigens and mimic natural infection. Our pioneering intranasal vaccine is poised to revolutionize the fight against infectious diseases, and by facilitating non-invasive immunization, we aim to enhance vaccination rates, ultimately safeguarding more individuals and communities. Dr. Priyabrata Pattnaik, Deputy Managing Director, Indian Immunologicals Limited added “This is a perfect example of Industry-Academia collaboration translating concepts to products for the benefit of people at large. Our R&D team has dedicated immense effort to the creation of this innovative vaccine, and we take pride in its proven safety and efficacy in generating a protective immune response with just a single dose” Nature Portfolio Griffith University #IndustryAcademiaCollaboration Click here to access the Nature Publication. https://lnkd.in/eKNq-F_Y Click the link below to read the full news article: https://lnkd.in/ehjPNQ9F

Celebrating freedom and the spirit of Independence! Happy Independence Day! 🇮🇳 #78thIndependenceDay #IndependenceDay

Indian Immunologicals Ltd has been engaging in many activities contributing significantly back to the society. A IIL sponsored GIFT MILK program under the National Foundation for Nutrition (NFN) was launched in Vettaikaranpudur VILLAGE, Coimbatore District, Tamil Nadu by Dr. Meenesh Shah, Chairman and MD of National Dairy Development Board and IIL in the presence of Guest of Honour Selvi Catherine Saranya IAS, Sub Collector of Pollachi, Dr. K. Anand Kumar, MD, IIL, the District Education Officer and many officials, invited guests, teachers and students from different schools. Under this program over 1000 children from various Government schools and those residing in Adivasi Tribal Hostels will be provided with 200 mL of flavoured, fortified milk everyday on all school days in the morning. This initiative will improve the overall health of young children as milk contains protein, carbohydrates, minerals, vitamins, immune defense proteins etc. A healthy India will indeed make a productive India. IIL has already been providing gift milk to more than 3500 school children in Tamil Nadu and Telangana. This initiative has been well appreciated by the teachers and school children and their parents.

Dr. Priyabrata Pattnaik, Deputy Managing Director of Indian Immunologicals Ltd joined ‘Brainstorming Session on Entrepreneurial Opportunities in Aquatic Animal Health Management’ organized ICAR-CIFE, Mumbai on 18 July 2024. This event was well attended by many industries representative dealing with fish health management, progressive fish farmers, scientist, academicians, and fisheries students. This event provided a platform linking Central Institute of Fisheries Education to Industry for student internships, co- development of technologies and mentoring & hand holding of student start-ups to promote entrepreneurship. IIL in partnership with Central Institute of Fisheries Education is developing vaccines for diseases common to freshwater fishes. Dr. Pattnaik also discussed potential regulatory pathways for fish vaccine development and alluded to safety, immunogenicity, potency, efficacy, and analytical assay method development in a separate meeting with subject matter experts from Division of Aquatic Environment & Health Management of ICAR-CIFE.

Chairman Indian Immunologicals Ltd (IIL) Dr. Meenesh Shah and Managing Director IIL visited Polyvac, a Government vaccine company established in Hanoi, Vietnam. IIL has jointly collaborated with Polyvac to produce much needed Measles-Rubella vaccine for India's Universal Immunization Programme. During the meeting, Dr. Hien (Director), Dr.Huong (Head of Manufacturing), Ms. Pham (Quality Assurance), Dr. Hai (AMV group) were present. A visit was also made to the testing facility near Halong Bay. National Dairy Development Board

Indian Immunologicals Ltd (IIL) led by its Chairman Dr. Meenesh Shah and its Managing Director Dr. K. Anand Kumar donated 10,000 doses of its anti-rabies vaccine to the economically backward people of 5 provinces in Vietnam. Click on the article below to know more: https://lnkd.in/drx6jzaY

10,000 doses of rabies vaccine donated to National Rabies Control Programme Click on the article below to know more: https://lnkd.in/dWqMZFQS